When you get placed on ignore for stating that NVIV has lost $160M in market cap in the last 60 days,I guess that means that some on this board actually love losing money! Unbelievable!
I reiterate 100 fold your comments. The vast majorigy of NVIV investors have lost money in a very big way. We all got screwed and shame on us. With only 8 patients enrolled, it will be a cold day in %$## before they expand into the UK and Canada. Mark my words - based on the way this thing has been trading, it's headed to a new 52-week low below $3.50.
Since NVIV topped out at $10.38 two short months ago, NVIV investors have lost a total of $160 Million. While NVIV continues to fall like a hot knife through butter, many of you here continue to buy. Green closes like yesterday (which are few and far between) pull suckers in thinking this thing will finally trade higher only to see it the very next day set a lower low. Something is wrong. Something is totally flawed - maybe it's the snail's pace of enrollments that if they do not pick up will destroy any financial models. Maybe it's incompetent management. Pick your Poisson. The run to $10+ started from the $4's and at this rate it will only take a couple more days before we return to the $4's once again. Cograts to management for losing $160M in market cap over the last 60 days!!!!
I was told by investor relations that Perrin's base salary is $421,395 plus option awards of $1,083,088 plus $215,000 Non-Equity Incentive Plan Compensation plus Other Compensation $200,618 = $1,920,101 and that his options would be totally worthless. Based on this comment it is obvious the folks at NVIV are more concerned about themselves than they are their shareholders. I reminded IR that NVIV stock has now lost nearly $150M in market cap since the Raymond James secondary. Losing $150M to bring in $30M in cash is extremely difficult to rationalize!
Perrin needs to be fired - end of discussion. No one has yet to give a legitimate answer as to why it's taking so long to enroll patients. The company needs to dramatically speed up enrollments to gain credibility that the device can find a big enough market out there once it is approved. Otherwise, this stock is headed for new 52-week lows.
The rise to $10 started from the $4's. Looks like that's where we're headed back to. For all of you who are pleased with the way Perrin has decreased shareholder value, please be sure to send him a box of chocolates.
Your statement concerning near term share appreciation is totally inaccurate and you know it! I do agree with you in that management has made progress although it is way too slow....8 patient enrollments in 18 months simply won't cut it. The slow rate of enrollment is likely the main issue with the stock's poor performance. If you have bought this stock and held it literally most any time over the last five years, you are down SIGNIFICANTLY on your investment. Would you like the numbers - both long-term and short-term?...5 year performance down 19%; 3 year performance down 36%; 2 year performance down 22%; one year performance down 50%; last two month performance down 38%; and finally.... down 71% from all-time high of less than two years ago. As it relates to Perrin's pay, I can name you several dozen other CEO's in the same sector whose pay is less than half of what Perrin makes and whose stock has performed 10 times better.... just on is SUPN. The SUPN CEO makes $916k and the market cap of SUPN is $833M versus a market cap for NVIV of $194M. When SUPN first went public back in 2012 its stock was priced at $4. Four years later its stock is priced near $17 and its stock is up 325%. These are the facts and I'll be more than happy to provide you with dozens of other examples. BOTTOM LINE - Mark Perrin is over paid and taking a pay raise - particularly based on the lack of performance of his stock is a slap in the face of retail shareholders. Since Perrin took his pay raise, our stock has lost $100 million in market cap - an absolutely pathetic disconnect with the retail shareholders who have lost their %$% - short term, medium term and long term!!!! I rest my case.
Perrin had it all planned..... Having a preplanned secondary at $7.50, he releases a bevy of positive press releases to drive his stock over the $10 level. He then announces the secondary and gives himself a fat pay raise, making $2M annually, while every investor alive got the shaft. Since the secondary his company's stock has lost $100 million in market cap and his shareholders are sucking wind but why should he care? He's got his fat paycheck....an absolute disgrace!!!
The thing that continues to get under my skin is Perrin's $2M salary. While all of his shareholders are losing their #$%$, he's making $2M - just not a good sign about giving a damn about shareholders. The guy should either be fired or at the very least his salary needs to be cut by at least 50% until he can prove he can create value for his shareholders - so far which he has failed miserable at!
Did you notice his disclaimer? He gets paid between $2k and $5k per month for each of the companies. I counted 72 companies - that's between $1.7M and $4.3M this guy is raking in annually. Wish I had noticed that before. To say the least, his judgment is clouded. Additionally, he's been dead wrong on NVIV.
Looks like you're going to have the opportunity to buy in the $4's....so load the boat!!!
So why has the market not recognized your rosy predictions? Company has stated they will reach full enrollment by year's end. Current enrollment rate is only 1 patient every 2+ months. Perhaps this is the problem with the lousy stock performance. To reach full enrollment by year's end, management needs to start enrolling more than two patients each month. They've already lost credibility in my book with some of the bonehead decisions. Enrollments need to dramatically pick up, otherwise they will lose any credibility they already have - which isn't much! A pickup in enrollments will hopefully gain credibility among investors that the device can find a big enough market out there once it is approved.
July Silver powered out to a new high close today and the next resistance target is a full $1.00 higher. June Gold is still the caboose on this bullish train, but it looks okay and headed for 1317.... bottom line - GPL will soon be priced above $3.00
Here's a well thought through, educated answer to your post.... The Company still hopes to finish enrollment of the remaining 13 subjects by the end of this year. While at the current pace this completion of enrollment of 13 more by the end of this year seems hard to believe, having a 5th success even before then seems quite likely. However, the Company needs to speed up enrollments to gain credibility that the device can find a big enough market out there once it is approved ... i.e., that there are indeed 3,000-4,000 potential uses per year, or the financial model projections we’ve seen don't hold water.
How many more months or years are we to use the word "hopefully" in our comments about our investment in NVIV? That's starting to wear very thin.
Believe me - I go back that far too.... Tuesday's gains have all but evaporated - only took two days and now we're back below both the 9- and 20-dma....pathetic!!
that we're dealing with a seriously flawed stock and for anyone on this board to say that NVIV is a risk free investment is simply unbelievable. The vast majority of NVIV investors who have owned this stock for any length of time at all are seriously in the red. Once again the stock is resuming its same old trading pattern. Good news brings in a rush of buying for a one day advance and then the selling continues. Tuesday's buying took us to a high of $7.10, closing back above the 50dma for the first time in over a week. We stayed above the 50-day for two whopping days and now today we are once again trading back below the 50-day at $6.50 so if you were the unfortunate soul who bought NVIV on Tuesday at $7.10, you're already down 8.45%. Based on the trading history of NVIV over the last several years, I'm beginning to think that not even FDA approval will save us!
CEO compensations versus stock performance & market cap......
Supernus Pharmaceuticals (SUPN - $17.54) among the fastest growing biotech company's in the U.S. with 70% annualized EPS growth over the next five years. EPS expected to grow from $.32 in 2014 to $2.06 by 2018. CEO Jack A Khathar's annual salary $916k. Stock is up 257% from a 2013 low of $4.90. Market Cap $866M
Pacira Pharmaceuticals (PCRX - $60.06) annualized EPS growth of 77% over the next 5 years...expected to increase EPS from $.37 per share in 2014 to $4.35 BY 2018. Full time employees 487 - CEO David Stack's annual salare $1.22M. Stock up 213% from 2013 low of $19.12. Market Cap $2.23B
Ligand Pharmaceuticals (LGND - $130.11) annualized EPS growth of 45%. Stock up 546% from 2013 low of $19.12. CEO John Higgins annual salary $945k. Market Cap $2.7B
Anavex Life Sciences (AVXL - $6.06) Alzheimer's drug in clinical trials. CEO Christopher Missling's annual salary $1.37M. Stock up 1,217% from a 2013 low of $.46. Market Cap $216M
Kite Pharma (KITE - $49.06) Stock up 129% from a 2013 low of $21.39. CEO Dr, Arie Belldegrun's annual salary $863k. Clinical stage biotech company. Market Cap $2.45B
InVivo Therapeutics (NVIV - $5.98) Stock uo 35% from 2013 low of $4.40 but down 75% from its 2013 high. CEO Mark Perrin's annual salary $1.92M. NVIV's market cap is the lowest of the group - less than one-tenth the market caps of PCRX, LGND and KITE. NVIV's stock performance is the worst in the group yet Mark Perrin's salary is the highest in the group.